Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from TempraMed Technologies Ltd. ( (TSE:VIVI) ).
TempraMed Technologies has launched VIVI Med, a new temperature-protection product designed for medication vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors and temperature- and light-sensitive glucose test strips, extending its technology beyond the insulin-pen format. By adding this multi-format solution to its existing VIVI Cap and VIVI Epi offerings, TempraMed significantly broadens its addressable market to include high-cost biologics users, healthcare providers, specialty pharmacies and institutional B2B partners, diversifying revenue streams and reducing dependence on any single medication format while strengthening its long-term growth profile and commercial reach in the expanding biologics and specialty injectables sector.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a medical-technology company specializing in temperature-controlled medication storage solutions, using proprietary, patented, space-grade thermal insulation to protect temperature-sensitive drugs. The company’s FDA-registered products have focused primarily on insulin pens and epinephrine auto-injectors, targeting patients, healthcare providers and institutional channels that require reliable, portable, power-free thermal protection for critical medications.
Average Trading Volume: 42,034
Current Market Cap: C$66.09M
See more data about VIVI stock on TipRanks’ Stock Analysis page.